Bronnen:
Dimopoulos MA, Lonial S, White D, et al. Eloquent-2 update: A phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma - 3-year safety and efficacy follow-up. Blood 2015 126:23;28.,Dimopoulos MA, Lonial S, White D, et al. Phase 3 ELOQUENT-2 study: extended 4-year follow-up of elotuzumab plus lenalidomide/dexamethasone vs lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. EHA 2017, abstract S456.
Dimopoulos MA, Lonial S, White D, et al. Eloquent-2 update: A phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma - 3-year safety and efficacy follow-up. Blood 2015 126:23;28.,Dimopoulos MA, Lonial S, White D, et al. Phase 3 ELOQUENT-2 study: extended 4-year follow-up of elotuzumab plus lenalidomide/dexamethasone vs lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. EHA 2017, abstract S456.